百忧解可抑制多发性硬化活动性

点击:次 更新日期:2008年11月15日

(《今日医学新闻》2008年5月3日报道)

 

A new study published in the Journal of Neurology Neurosurgery and Psychiatry finds that Prozac, a commonly prescribed antidepressant, may be an agent in slowing down the disease process of the relapsing remitting form of multiple sclerosis (MS).

在《神经病学、神经外科学及精神病学》期刊上发表的一项新的研究发现,处方常用抗抑郁药百忧解,可能延缓复发-缓解型多发性硬化的病程。

Multiple sclerosis is an autoimmune disease where the immune system attacks the central nervous system. In the relapsing remitting form, new symptoms occur in discrete attacks. 

多发性硬化(MS)是一种自身免疫性疾病,表现为免疫系统攻击中枢神经系统。复发-缓解型多发性硬化的新的症状出现于离散性攻击中。

A team of researchers led by J P Mostert (Department of Neurology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands) conducted a double-blind, placebo-controlled, exploratory analysis of 40 patients with the relapsing remitting form of MS. For a period of 24 weeks, half of the sample was treated with 20 mg daily of fluoxetine (Prozac) while the other half received a placebo. To measure the activity of MS, detailed magnetic resonance images (MRI) of the participants' brains were completed every four weeks. The researchers focused on areas of neurological inflammation that would indicate active disease.

荷兰格罗宁根大学医学中心神经病学系的J•P•摩斯特特(J P Mostert)所领导的研究小组采用双盲、设立安慰剂对照组检测分析了40名复发-缓解型多发性硬化患者。在24周时间内,20名患者每天摄入百忧解20毫克,另外的20名患者给予安慰剂。 为测量MS的活动性,每4周一次对参与实验的患者的大脑进行详细的核磁共振成像(MRI)。研究者的观察集中于神经炎性反应发生区域。

Of the 40 initial patients, 19 participants in each group finished the study. The main finding was that the patients who were treated with Prozac had fewer new areas of inflammation than those treated with placebo. The researchers were able to detect the effects just after eight weeks - the same amount of time that it takes for selective serotonin reuptake inhibitor (SSRI) drugs such as Prozac to begin relieving depression.

最初的40名患者,每组有19名完成了实验。实验的主要发现是摄入百忧解的实验组患者的大脑神经系统发生新的炎症区域远较摄入安慰剂的对照组发生新的炎症区域少。研究者在实验开始后8周即可检测到此效应, 而诸如百忧解等选择性复合胺再吸收抑制剂(SSRI)开始舒缓抑郁的作用时间也是8周。

Specifically, the group given placebo had an average of over five new areas affected with inflammation compared to just less than two areas in the Prozac group. Twenty-five percent of scans from Prozac-treated patients and forty percent of placebo-treated patients depicted new areas of inflammation. Almost two out of three patients in the Prozac group had no new inflammation areas during the last 16 weeks of treatment, whereas only about 25% of patients in the placebo group had no new areas.

尤其是,摄入安慰剂的对照组平均有超过五个新的炎症区域,而摄入百忧解的实验组只有少于两个新的炎症区。摄入百忧解的患者中的25%、摄入安慰剂患者的40%的扫描图显示了新的炎症区。实验组中差不多三分之二的患者在治疗的最后16周中未见有新的炎症区域出现,而只有25%的对照组患者无新的炎症区出现。

Although this was a small-scale study and a larger sample size is required to increase the robustness of results, the authors conclude that, "Results of our exploratory trial are sufficiently encouraging to justify further studies with fluoxetine in patients with MS. Higher doses of fluoxetine and combination treatment with immunomodulatory drugs should be considered." 

虽然这只是一个小规模的研究、需更大的试样量来提高结果的可靠性,论文作者总结道,“我们的测试结果足以鼓励进一步研究百忧解对MS患者的影响是正当的。 应该考虑摄入更高剂量的百忧解以及结合免疫调节药物的联合治疗。


上一篇:没有了 下一篇:“伟哥”有助改善女人性功能障碍
常见疾病